Baker McKenzie suggested Bayer on the antitrust and competitors features of its world unique license and collaboration in precision oncology with Kumquat Biosciences, Inc.
Bayer and Kumquat, a clinical-stage biotech firm based by pioneers of the KRAS pathway, introduced 12 August that they’ve entered into an unique world license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor. Beneath the settlement, Kumquat is chargeable for the initiation and completion of the Section Ia research, whereas Bayer will full improvement and industrial actions.
Kumquat obtained US Meals and Drug Administration (FDA) clearance of the investigational new drug (IND) for its KRAS G12D inhibitor in July 2025. Beneath the phrases of the settlement, Kumquat will obtain as much as USD 1.3 billion, together with upfront, medical and industrial milestones, and extra tiered royalties on web gross sales. Kumquat retains an unique possibility to barter for taking part in profit-loss sharing within the US.
Led by Creighton Macy, Chair of Baker McKenzie’s World Antitrust Group, the core Baker McKenzie workforce advising on the deal included Nicolas Kredel, Jan Kresken, Duk-ki Moon, and Marisa Dieken.
Study extra concerning the deal on PR Newswire.
Baker McKenzie’s globally main Antitrust & Competitors Observe is without doubt one of the largest on this planet with greater than 300 practitioners throughout 60 workplaces and 43 international locations. Persistently acknowledged as a world chief, the group handles a broad spectrum of advanced competitors regulation issues, together with antitrust litigation, antitrust company investigations, legal and civil enforcement instances, and merger clearance issues. The workforce additionally often offers antitrust compliance steerage and coaching for purchasers.
Bayer and Kumquat, a clinical-stage biotech firm based by pioneers of the KRAS pathway, introduced 12 August that they’ve entered into an unique world license and collaboration to develop and commercialize Kumquat’s KRAS G12D inhibitor. Beneath the settlement, Kumquat is chargeable for the initiation and completion of the Section Ia research, whereas Bayer will full improvement and industrial actions.
Kumquat obtained US Meals and Drug Administration (FDA) clearance of the investigational new drug (IND) for its KRAS G12D inhibitor in July 2025. Beneath the phrases of the settlement, Kumquat will obtain as much as USD 1.3 billion, together with upfront, medical and industrial milestones, and extra tiered royalties on web gross sales. Kumquat retains an unique possibility to barter for taking part in profit-loss sharing within the US.
Led by Creighton Macy, Chair of Baker McKenzie’s World Antitrust Group, the core Baker McKenzie workforce advising on the deal included Nicolas Kredel, Jan Kresken, Duk-ki Moon, and Marisa Dieken.
Study extra concerning the deal on PR Newswire.
Baker McKenzie’s globally main Antitrust & Competitors Observe is without doubt one of the largest on this planet with greater than 300 practitioners throughout 60 workplaces and 43 international locations. Persistently acknowledged as a world chief, the group handles a broad spectrum of advanced competitors regulation issues, together with antitrust litigation, antitrust company investigations, legal and civil enforcement instances, and merger clearance issues. The workforce additionally often offers antitrust compliance steerage and coaching for purchasers.
